In breast cancers, RAS is often activated by HER2 [ErbB2/epidermal growth factor receptor (EGFR) 2/Neu] receptor tyrosine kinase and is over expressed and persistently activated in approximately 25 % of cancers [48]. The gene discussed is EGFR; the disease is breast carcinoma.